Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
about
Population pharmacokinetics of amphotericin B in children with malignant diseasesSusceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrPharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelOptimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.
P2860
Q28365933-E340E7D5-A634-41B8-B5B7-BECC3FBACADDQ33622932-C6C47D87-1B50-4614-A117-8C37127D4517Q33978188-BAA13B30-7C8D-4673-B4E7-E6A154451CEDQ34113512-B33FC0AF-469B-4F9D-963F-14AD111E7EBFQ35666627-263AA5E1-7BD2-4C60-9CE2-C1F7BAA5097BQ35746264-43E98263-07FA-4D57-81E6-3B3155C1AE1CQ37036445-C564C793-982D-4C0D-A154-1E580003A278Q38653256-316ABDD5-70AB-41EA-B182-1523F6845232Q38681635-28D35CB5-5AE1-4FFA-96BA-2F53702E23BAQ39470922-BEC17EE4-AC69-489E-977D-E3A3D22D06FDQ39476255-14CF6058-D641-4091-979B-94742E8CEB81Q55488494-AD887018-CACE-4FC4-93F0-9E8EC8A5A953
P2860
Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մարտին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Pharmacokinetics of convention ...... of patients with neutropenia.
@ast
Pharmacokinetics of convention ...... of patients with neutropenia.
@en
type
label
Pharmacokinetics of convention ...... of patients with neutropenia.
@ast
Pharmacokinetics of convention ...... of patients with neutropenia.
@en
prefLabel
Pharmacokinetics of convention ...... of patients with neutropenia.
@ast
Pharmacokinetics of convention ...... of patients with neutropenia.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of convention ...... p of patients with neutropenia
@en
P2093
Ayestarán A
Estíbalez A
Montoro JB
P2860
P304
P356
10.1128/AAC.40.3.609
P407
P577
1996-03-01T00:00:00Z